Commentary on the Second Quarter 2026 Report

CEO Sofia Heigis and CFO Henrik Bergentoft share their perspectives on Oncopeptides’ second-quarter 2026 report, including 62 percent growth, the newly signed distribution agreement with Salus Group for Central and Eastern Europe, and the recently submitted type II variation to the EMA that could expand Pepaxti’s addressable patient population by up to twofold. They also discuss progress in the glioblastoma study in Oslo, where the first patient has now been dosed. In Swedish only.